Methods of correction of hypogonadism syndrome in men and long-term results of drug treatment
E. R. Rozhivanova,
R. V. Rozhivanov,
E. V. Morozova,
K. E. Gaidaichuk,
G. A. Mel’nichenko,
E. N. Andreeva,
N. G. Mokrysheva https://doi.org/10.14341/brh12770
Abstract
Hypogonadism syndrome, characterized by testosterone deficiency, negatively affects the physical, metabolic and psychoemotional health of men. The main treatments for hypogonadism include androgen replacement and androgen stimulating therapy. Androgen replacement therapy, represented by transdermal and injectable forms of testosterone, effectively restores testosterone levels, improves sexual function, muscle mass, bone mineral density and metabolic parameters.
However, it suppresses spermatogenesis, which limits its use in men planning fatherhood. Androgen stimulating therapy, including gonadotropins, antiestrogens and aromatase inhibitors, stimulates the production of endogenous testosterone and spermatogenesis. Gonadotropins demonstrate high efficacy, but their long-term use is complicated by the need for frequent injections and the lack of long-term results. The long-term studies presented in the review confirm the safety and effectiveness of androgen replacement therapy, but data on androgen stimulating therapy are limited in follow-up time to a maximum of two years.
About the Authors
E. R. Rozhivanova
Endocrinology Research Centre
Russian Federation
Competing Interests:
Russian Federation
Ekaterina R. Rozhivanova - MD.
11 Dm. Ulyanova street, 117036 Moscow
Competing Interests:
none
R. V. Rozhivanov
Endocrinology Research Centre
Russian Federation
Competing Interests:
Russian Federation
Roman V. Rozhivanov - MD, PhD.
Moscow
Competing Interests:
none
E. V. Morozova
Endocrinology Research Centre
Russian Federation
Competing Interests:
Russian Federation
Elena V. Morozova - MD.
Moscow
Competing Interests:
none
K. E. Gaidaichuk
Endocrinology Research Centre
Russian Federation
Competing Interests:
Russian Federation
Konstantin E. Gaidaichuk - MD.
Moscow
Competing Interests:
none
G. A. Mel’nichenko
Endocrinology Research Centre
Russian Federation
Competing Interests:
Russian Federation
Galina A. Mel’nichenko - MD, PhD, Professor.
Moscow
Competing Interests:
none
E. N. Andreeva
Endocrinology Research Centre; Russian University of Medicine
Russian Federation
Competing Interests:
Russian Federation
Elena N. Andreeva - MD, PhD, Professor.
Moscow
Competing Interests:
none
N. G. Mokrysheva
Endocrinology Research Centre
Russian Federation
Competing Interests:
Russian Federation
Natalya G. Mokrysheva - MD, PhD, Professor.
Moscow
Competing Interests:
none
References
1. Tajar A, Huhtaniemi IT, O’Neill TW, et al. Characteristics of Androgen Deficiency in Late-Onset Hypogonadism: Results from the European Male Aging Study (EMAS). J Clin Endocrinol Metab. 2012;97(5):1508-1516. doi: https://doi.org/10.1210/jc.2011-2513
2. Al-Sharefi A, Quinton R. Current National and International Guidelines for the Management of Male Hypogonadism: Helping Clinicians to Navigate Variation in Diagnostic Criteria and Treatment Recommendations. Endocrinol Metab (Seoul). 2020;35(3):526-540. doi: https://doi.org/10.3803/EnM.2020.760
3. Salonia A, Bettocchi C, Carvalho J, et al. EAU Guidelines on Sexual and Reproductive Health 2021 Update: Male Sexual Dysfunction. Eur Urol . 2021. Аvailable on the EAU website: http://www.uroweb.org/guidelines/
4. Wang C, Nieschlag E, Swerdloff R, et al. Investigation, Treatment, and Monitoring of Late-Onset Hypogonadism in Males: ISA, ISSAM, EAU, EAA, and ASA Recommendations. Eur Urol. 2009;55(1):121-130. doi: https://doi.org/10.1016/j.eururo.2008.08.033
5. Zitzmann M. Testosterone, mood, behaviour and quality of life. Andrology. 2020;8(6):1598-1605. doi: https://doi.org/10.1111/andr.12867
6. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society* Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. doi: https://doi.org/10.1210/jc.2018-00229
7. Pencina K.M., Travison T.G., Cunningham G.R. et al. (2024). Effect of Testosterone Replacement Therapy on Sexual Function and Hypogonadal Symptoms in Men with Hypogonadism. The Journal of Clinical Endocrinology & Metabolism, 109(2), 569–580. doi: https://doi.org/10.1210/clinem/dgad484
8. Lee TW, Kao PY, Chen YC, Wang S Te. Effects of Testosterone Replacement Therapy on Muscle Strength in Older Men with Low to Low-Normal Testosterone Levels: A Systematic Review and Meta-Analysis. Gerontology. 2023. doi: https://doi.org/10.1159/000532062
9. Saad F, Haider KS, Haider A. Effects of long-term testosterone therapy on anthropometric parameters in men with functional hypogonadism and obesity: 12-year observational data from a controlled registry study in a urological setting. Endocr Abstr. May 2021. doi: https://doi.org/10.1530/endoabs.73.AEP162
10. Borges MD J. The Inverse Association between Testosterone Replacement Therapy and Cardiovascular Disease Risk: A Systematic 25-year Review and Meta-Analysis Analysis of Prospective Cohort Studies from 1999 to 2024. International Journal of Cardiovascular Medicine. 2024;3(4):01–8. doi: https://doi.org/10.31579/2834-796X/073
11. Brannigan RE. Testosterone Therapy and Male Fertility. / Controversies in Testosterone Deficiency. 2021; р. 57–70. doi: https://doi.org/10.1007/978-3-030-77111-9_6
12. Kanakis GA, Nordkap L, Bang AK, et al. EAA clinical practice guidelines—gynecomastia evaluation and management. Andrology. 2019. doi: https://doi.org/10.1111/andr.12636
13. Kienitz T, Quinkler M. Testosterone and blood pressure regulation. Kidney Blood Press Res. 2008. doi: https://doi.org/10.1159/000119417
14. Frizza F, Maggi M, Lotti F. Skin Androgen-Related Disorders: Hormonal Treatment. / European Handbook of Dermatological Treatments. 2023; p.1661–1678. doi: https://doi.org/10.1007/978-3-031-15130-9_147
15. Nackeeran S, Kohn T, Gonzalez D, White J, Ory J, Ramasamy R. Association between testosterone therapy and change in hematocrit: a systematic review and network metaanalysis of randomized control trials. Fertil Steril. 2021. doi: https://doi.org/10.1016/j.fertnstert.2021.07.960
16. Lenfant L, Leon P, Cancel-Tassin G, et al. Testosterone replacement therapy (TRT) and prostate cancer: An updated systematic review with a focus on previous or active localized prostate cancer. Urol Oncol Semin Orig Investig. 2020;38(8):661-670. doi: https://doi.org/10.1016/j.urolonc.2020.04.008
17. Bhasin S, Travison TG, Pencina KM, et al. Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism. JAMA Netw Open. 2023;6(12):e2348692. doi: https://doi.org/10.1001/jamanetworkopen.2023.48692
18. Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023. doi: https://doi.org/10.1056/nejmoa2215025
19. Čeponis J, Yuen F, Swerdloff RS, Wang C. Testosterone Therapy: Transdermal Androgens. / Testosterone. 2023; p.303–314. doi: https://doi.org/10.1007/978-3-031-31501-5_14
20. Instruktsiia po meditsinskomu primeneniiu lekarstvennogo preparata «Androgel®». Registratsionnyi nomer: LS-000869. Gosudarstvennyi reestr lekarstvennykh sredstv
21. Hill, Alyssa MD; Rabaza, Cristina MD. (2024). Is topical testosterone less likely to cause polycythemia than IM testosterone in patients on testosterone replacement therapy?. Evidence-Based Practice, 27(6), 17–18, June 2024. doi: https://doi.org/10.1097/EBP.0000000000002101
22. Yassin A. Testosterone Therapy: Injectable Androgens. / Testosterone. 2023; р.315–330. doi: https://doi.org/10.1007/978-3-031-31501-5_15
23. Instruktsiia po meditsinskomu primeneniiu lekarstvennogo preparata «Sustanon®-250». Registratsionnyi nomer: P N013419/01. Gosudarstvennyi reestr lekarstvennykh sredstv
24. Instruktsiia po meditsinskomu primeneniiu lekarstvennogo preparata «Omnadren® 250». Registratsionnyi nomer: P N014397/01. Gosudarstvennyi reestr lekarstvennykh sredstv
25. Instruktsiia po meditsinskomu primeneniiu lekarstvennogo preparata «Nebido®». Registratsionnyi nomer: LP-№(004023)-(RG-RU). Gosudarstvennyi reestr lekarstvennykh sredstv
26. [Instruktsiia po meditsinskomu primeneniiu lekarstvennogo preparata «Testosterona propionat». Registratsionnyi nomer: LP-№(004825)-(RG-RU). Gosudarstvennyi reestr lekarstvennykh sredstv
27. Ide V, Vanderschueren D, Antonio L. Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy. Int J Mol Sci. 2020;22(1):21. doi: https://doi.org/10.3390/ijms22010021
28. Boeri L, Capogrosso P, Salonia A. Gonadotropin Treatment for the Male Hypogonadotropic Hypogonadism. Curr Pharm Des. 2021;27(24):2775-2783. doi: https://doi.org/10.2174/1381612826666200523175806
29. Instruktsiia po meditsinskomu primeneniiu lekarstvennogo preparata «Khoragon®». Registratsionnyi nomer: P N012469/01. Gosudarstvennyi reestr lekarstvennykh sredstv
30. Instruktsiia po meditsinskomu primeneniiu lekarstvennogo preparata «Gonadotropin khoriionicheskii». Registratsionnyi nomer: LP-№(007553)-(RG-RU). Gosudarstvennyi reestr lekarstvennykh sredstv
31. Jeon G-H, Park C. Successful pregnancy after hCG/hMG treatment in an azoospermic male with idiopathic hypogonadotropic hypogonadism. Indones J Obstet Gynecol. October 2022:238-242. doi: https://doi.org/10.32771/inajog.v10i4.1604
32. Kim ED, Crosnoe L, Bar-Chama N, Khera M, Lipshultz LI. The treatment of hypogonadism in men of reproductive age. Fertil Steril. 2013;99(3):718-724. doi: https://doi.org/10.1016/j.fertnstert.2012.10.052
33. Huijben M, Huijsmans RLN, Lock MTWT, de Kemp VF, de Kort LMO, van Breda JHMK. Clomiphene citrate for male infertility: A systematic review and meta‐analysis. Andrology. 2023;11(6):987-996. doi: https://doi.org/10.1111/andr.13388
34. Instruktsiia po meditsinskomu primeneniiu lekarstvennogo preparata «Klostilbegit®». Registratsionnyi nomer: LP-№(000161)-(RG-RU). Gosudarstvennyi reestr lekarstvennykh sredstv
35. Wu YC, Sung WW. Clomiphene Citrate Treatment as an Alternative Therapeutic Approach for Male Hypogonadism: Mechanisms and Clinical Implications. Pharmaceuticals (Basel). 2024;17(9):1233. doi: https://doi.org/10.3390/ph17091233
36. Awouters M., Vanderschueren D. & Antonio L. (2020). Aromatase inhibitors and selective estrogen receptor modulators: Unconventional therapies for functional hypogonadism? Andrology, 8(6), 1590–1597. Portico. https://doi.org/10.1111/andr.12725
37. Huang WJ. The Roles of Aromatase Inhibitors in Treating Hypogonadism and Male Infertility. Urol Sci. 2022;33(3):114-118. doi: https://doi.org/10.4103/UROS.UROS_28_22
38. Instruktsiia po meditsinskomu primeneniiu lekarstvennogo preparata «Anastrozol-Promomed». Registratsionnyi nomer: LP-№(005165)-(RG-RU). Gosudarstvennyi reestr lekarstvennykh sredstv
39. Instruktsiia po meditsinskomu primeneniiu lekarstvennogo preparata «Letrozol». Registratsionnyi nomer: LP-№(006372)-(RG-RU). Gosudarstvennyi reestr lekarstvennykh sredstv
40. Kravtsova NS, Rozhivanov RV, Kurbatov DG. Stimulation of a spermatogenesis at men gonadotrophins and an antiestrogen at a pathospermia and infertility. Problems of Endocrinology. 2016;62(2):37-41. (In Russ.) doi: https://doi.org/10.14341/probl201662237-41
41. Saylam B, Efesoy O, Çayan S. The effect of aromatase inhibitor letrozole on body mass index, serum hormones, and sperm parameters in infertile men. Fertil Steril. 2011;95(2):809-811. doi: https://doi.org/10.1016/j.fertnstert.2010.09.021
42. Wang C, Cunningham G, Dobs A, et al. Long-Term Testosterone Gel (AndroGel) Treatment Maintains Beneficial Effects on Sexual Function and Mood, Lean and Fat Mass, and Bone Mineral Density in Hypogonadal Men. J Clin Endocrinol Metab. 2004. doi: https://doi.org/10.1210/jc.2003-032006
43. Fillo J, Breza J, Ondrusova M, et al. Results of long term testosterone replacement therapy in men with abdominal obesity, erectile dysfunction and testosterone deficiency. Bratislava Med J. 2018;119(09):577-580. doi: https://doi.org/10.4149/BLL_2018_061
44. Brooke J., Walter D., Muraleedharan V. & Jones T. H. (2012). Testosterone replacement therapy has beneficial effects on Cardiovascular risk factors and liver function in hypogonadal men. Society for Endocrinology BES 2012, United Kingdom. Endocrine Abstracts 28 P163
45. Alwani M, Al-Zoubi RM, Al-Qudimat A, et al. The impact of longterm Testosterone Therapy (TTh) in renal function (RF) among hypogonadal men: An observational cohort study. Ann Med Surg. 2021. doi: https://doi.org/10.1016/j.amsu.2021.102748
46. Liu PY, Wishart SM, Handelsman DJ. A Double-Blind, PlaceboControlled, Randomized Clinical Trial of Recombinant Human Chorionic Gonadotropin on Muscle Strength and Physical Function and Activity in Older Men with Partial Age-Related Androgen Deficiency. J Clin Endocrinol Metab. 2002;87(7):3125-3135. doi: https://doi.org/10.1210/jcem.87.7.8630
47. Liu P, Wishart S, Celermajer D, et al. Do reproductive hormones modify insulin sensitivity and metabolism in older men? A randomized, placebo-controlled clinical trial of recombinant human chorionic gonadotropin. Eur J Endocrinol. January 2003:55-66. doi: https://doi.org/10.1530/eje.0.1480055
48. Yang L., Zhang S. X., Dong Q. et al. (2012). Application of hormonal treatment in hypogonadotropic hypogonadism: more than ten years experience. International Urology and Nephrology, 44(2), 393–399. https://doi.org/10.1007/s11255-011-0065-0
49. Bayram F, Elbuken G, Korkmaz C, Aydogdu A, Karaca Z, Caklr I. The Effects of Gonadotropin Replacement Therapy on Metabolic Parameters and Body Composition in Men with Idiopathic Hypogonadotropic Hypogonadism. Horm Metab Res. 2015. doi: https://doi.org/10.1055/s-0035-1564252
50. Habous M, Giona S, Tealab A, et al. Clomiphene citrate and human chorionic gonadotropin are both effective in restoring testosterone in hypogonadism: a short-course randomized study. BJU Int. 2018. doi: https://doi.org/10.1111/bju.14401
51. Debruyne F. M. J., Behre H. M., Roehrborn C. G. et al. (2017). Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men. BJU International, 119(2), 216–224. Portico. doi: https://doi.org/10.1111/bju.13578
52. Roman V. Rozhivanov, Ekaterina R. Rozhivanova, Elena N. Andreeva, Galina A. Mel’nichenko, Natalya G. Mokrysheva. Sindrom gipogonadizma u muzhchin (uchebnoe posobie). – Moscow: FSBI «NMRC of Endocrinology» of the Ministry of Health of the Russian Federation, 2025:50.
53. Zucker I, Rainer Q, Pai RK, Ramasamy R, Masterson TA. Efficacy and Safety of Human Chorionic Gonadotropin Monotherapy for Men With Hypogonadal Symptoms and Normal Testosterone. Cureus. 2022. doi: https://doi.org/10.7759/cureus.25543
54. Rainer Q, Pai R, Zucker I, Ramasamy R, Masterson TA. The Safety of Human Chorionic Gonadotropin Monotherapy Among Men With Previous Exogenous Testosterone Use. Cureus. June 2022. doi: https://doi.org/10.7759/cureus.25826
Supplementary files
Review
For citations:
Rozhivanova E.R., Rozhivanov R.V., Morozova E.V., Gaidaichuk K.E., Mel’nichenko G.A., Andreeva E.N., Mokrysheva N.G. Methods of correction of hypogonadism syndrome in men and long-term results of drug treatment. Bulletin of Reproductive Health. 2025;4(3):12-19. (In Russ.) https://doi.org/10.14341/brh12770
Views:
33
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
